Dr. D'Andrea brings more than 25 years of experience in translational research in immunology to ImmuneID.
The announcement of Dr. D'Andrea as president and CSO follows the launch of the company last year with a USD 22m seed financing led by founding investor Longwood Fund. Participants in the financing included Arch Venture Partners, Pitango HealthTech, Alta Partners, In-Q-Tel, Xfund, and others.
ImmuneID plans to use this funding to develop therapeutic programs in areas including severe allergy, autoimmunity, oncology, and infectious disease.
In addition to her appointment at ImmuneID, Dr. D'Andrea joins the Longwood Fund as a Venture Partner.
Previously, Dr. D'Andrea was chief scientific officer of Kiniksa Pharmaceuticals. Before joining Kiniksa, D'Andrea was vice president and Global Head of Discovery for Immunology and Inflammation at Roche, where she was responsible for discovering and advancing multiple drug candidates to the clinic.
Prior to Roche, she was executive director and Section Head of Discovery Biology at SRI International, where she was responsible for developing strategies to advance drugs through discovery and into development.
Dr. D'Andrea received a Bachelor of Sciences, summa cum laude, from the University of Siena in Italy and a doctoral degree from the University of Florence while training at the Wistar Institute at the University of Pennsylvania.
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.
Based on technology developed by scientific founders Stephen Elledge (Harvard), Ben Larman (Johns Hopkins), and Tomasz Kula (Harvard), we are employing our massively parallel, multiplexed, and unbiased systems to develop therapeutics for autoimmunity, severe allergy, oncology and infectious disease.
ImmuneID was founded in 2020 by Longwood Fund and is headquartered in Cambridge, MA.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial